LONGEVITY & CELLULAR HEALTH / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to MOTS-c and NAD+ longevity research.
What does the MOTS-c peptide do?
In animal models and cell studies, MOTS-c activates AMPK — the cell's master energy-sensing kinase — by inhibiting enzymes in the folate cycle and de novo purine synthesis, causing the signaling molecule AICAR to accumulate [6]. In skeletal muscle this improves glucose uptake and insulin sensitivity. Under metabolic stress, MOTS-c can also travel to the nucleus and shift antioxidant and metabolic gene expression via NRF2 [5]. In aged mice, injected MOTS-c significantly improved running capacity, grip strength and gait [4]. In a human observational cohort, circulating MOTS-c independently predicted cardiovascular events and all-cause mortality [2]. There are no human efficacy trials of exogenous MOTS-c.
What are the negative side effects of MOTS-c?
There are no published human safety trials of exogenous MOTS-c, so its side-effect profile in people is genuinely unknown. In the animal studies, including aged mice receiving MOTS-c over weeks, no overt toxicity is reported [4]. Known cautions from the literature include: no validated human pharmacokinetics (rodent doses cannot be extrapolated); research-chemical supply chains mean product purity and identity are unverified; a mitochondrial DNA variant (m.1382A>C) is pro-diabetogenic and suggests effects are not uniform across populations; and MOTS-c is prohibited in elite sport [1][2]. This site does not advise on use.
Is MOTS-c legal to buy?
In most jurisdictions, MOTS-c is sold as a research chemical — meaning it is legal to purchase for laboratory research purposes. It is not a controlled substance in most countries. However, it is specifically prohibited in sport under WADA and USADA anti-doping rules under the hormone-and-metabolic-modulator category [1]; an athlete who uses it risks sanctions. It is not an approved drug or supplement and is not sold for human consumption. Regulatory status varies by jurisdiction, and this site does not advise on legality for any individual situation.
How often do you inject MOTS-c?
This site does not advise on dosing or administration schedules for any compound. In the published animal research, MOTS-c has been administered by daily subcutaneous or intraperitoneal injection in mouse studies at doses ranging from approximately 0.5 to 15 mg/kg per day [4][6]. These are research parameters in rodents — they cannot be extrapolated to human dosing, and no human pharmacokinetic data exist to establish a safe or effective human regimen. Readers interested in any clinical application should consult a licensed clinician in their jurisdiction.
What is NAD supplement used for?
NAD+ precursors (primarily NMN and NR) are marketed and researched as supplements for boosting cellular NAD+ levels, which decline with age. In published human trials, oral NMN improved blood NAD+, walking distance and quality-of-life scores in middle-aged adults [9] and improved muscle insulin sensitivity in prediabetic women [10]. NR raised blood NAD+ dose-dependently with good tolerability [12]. Mechanistically, restoring NAD+ is thought to support sirtuin and PARP signaling — the enzymes that govern gene regulation, DNA repair, and inflammation [11]. A 2025 review notes that despite those signals, evidence for hard clinical outcomes (longevity, disease prevention) in humans remains limited [8].
What is the downside of taking NAD+?
Several downsides appear in the literature. First, plain oral NAD+ itself is poorly taken up by cells intact; NMN and NR are considered more rational oral precursors. Second, raising blood NAD+ is well demonstrated but translating that to hard clinical outcomes (longer healthspan, prevented disease) has not been shown convincingly in humans [8]. Third, IV NAD+ infusions can cause chest/abdominal discomfort, flushing and nausea and carry contamination risks — a compounded injectable NAD+ was subject to an FDA Class I recall for elevated bacterial endotoxin. Fourth, a theoretical concern exists that boosting NAD+ could fuel cancer-cell metabolism in people with existing tumors. Fifth, NMN's supplement regulatory status is contested in the US [8].
Is it safe to take NAD daily?
Human trials of oral NMN (up to 900 mg/day for 60 days) and oral NR (up to 1000 mg/day for 8 weeks) have not identified significant adverse effects or safety concerns [9][12]. NR did not elevate LDL cholesterol or disrupt one-carbon metabolism at any dose [12]. That said, these are relatively short trials in adults without serious illness; long-term safety over years, effects in people with cancer or at elevated cancer risk, and effects in frail elderly populations are not established. This site summarizes the research and does not advise on use; readers should consult a clinician.
Does NAD cause weight gain?
The published human trials do not show NAD+ precursors causing weight gain. In the multicenter NMN trial, body weight and body composition were not significantly different between treatment and placebo groups [9]. MOTS-c — the other compound on this desk — actually prevented diet-induced obesity in mice in the founding study [6], and is sometimes discussed in fat-loss contexts. However, neither compound has demonstrated weight loss or weight gain as a reliable outcome in controlled human trials. No compound discussed here should be construed as a weight-management intervention. This site does not advise on use.
What is the difference between NAD+, NMN and NR?
NAD+ is the coenzyme itself — the active form inside cells that accepts and donates electrons and feeds sirtuin and PARP enzymes. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors: smaller molecules the cell converts into NAD+ through enzymatic steps. Oral NAD+ itself is poorly absorbed intact by cells; oral NMN and NR are taken up by intestinal transporters and then converted to NAD+ inside cells. Human trials have been conducted with both NMN and NR and both reliably raise blood NAD+ [9][12]. Whether NMN or NR is superior for tissue-level NAD+ elevation remains an active research question [8][11].
Are MOTS-c and NAD+ related?
They are related by cellular context, though they are structurally very different. Both tie back to mitochondrial biology: MOTS-c is encoded inside the mitochondrial genome and acts partly by activating AMPK — the energy sensor that responds to low ATP [6] — while NAD+ is the redox coenzyme that mitochondria use to generate that ATP and a substrate for sirtuins, which regulate the same metabolic gene programs AMPK controls [11]. In a sense, MOTS-c can be understood as a signal that upregulates AMPK activity when energy supply tightens, while NAD+ is the substrate whose abundance determines how well those programs run. They are not the same molecule, they have different mechanisms, and they have been studied in very different human-evidence contexts.
Where can I find the sources cited on this site?
All citations are aggregated on the references page, numbered consistently across every page on this desk. Each entry includes authors, title, journal, year, DOI and a PubMed or PMC link where available. Sources are limited to peer-reviewed journal articles, reviews published in indexed journals, and — where cited — regulatory-agency documents. This site cites only sources it has verified; no citation appears here without a confirmed DOI, PMID, or PMC identifier.